The Pharma Data

OCTOBER 23, 2020

14 in Infection Control & Hospital Epidemiology , updated recommendations are presented for the management of health care personnel (HCP) living with hepatitis and HIV. from the National Institutes of Health in Bethesda, Maryland, and colleagues updated guidance for HCP with HIV and hepatitis, reflecting advances in care and treatment.

RNA 52

RNA Virus Vaccine Hospitals 52

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. This press release features multimedia.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

APRIL 22, 2023

Additional data includes a retrospective real-world study which demonstrated that Veklury treatment is associated with a lower risk of death from COVID-19 for people living with cancer. Since the beginning of the pandemic, Veklury has played a critical role in the treatment of hospitalized patients with COVID-19.

Hospitals 40

Hospitals Virus Treatment Pharmacokinetics 40

NIH Director's Blog: Drug Development

NOVEMBER 16, 2021

The first indication that those hopes might be realized came from the announcement just a month ago of a 50 percent reduction in hospitalizations from the Merck and Ridgeback drug molnupiravir (originally developed with an NIH grant to Emory University, Atlanta). The drug targets a highly conserved, but essential, viral enzyme.

Clinical Trials 52

Clinical Trials Virus Hospitals FDA 52

PLOS: DNA Science

JULY 27, 2023

The owners of the felines all reported feeding their pets raw meat, and samples of the meat revealed not only flu virus genetic material, but also infectious virus. The fear is that a variant of the deadly virus might emerge that infects people, and, worst-case-scenario, passes from person to person. emerged in late 2021.

Disease 92

Disease DNA Virus RNA 92

The Pharma Data

JULY 12, 2021

The Phase 3 portion of the global MOVe-OUT trial studying molnupiravir in non-hospitalized adult patients with laboratory-confirmed COVID-19 and at least one risk factor associated with poor disease outcomes is underway. This press release features multimedia. View the full release here: [link]. “It

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories Hospitals 52

The Pharma Data

SEPTEMBER 1, 2021

MOVe-AHEAD (MK-4482-013) ( NCT04939428 ) is a Phase 3 multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered molnupiravir compared to placebo in preventing the spread of SARS-CoV-2, the virus that causes COVID-19, within households.

Laboratories 52

Laboratories Virus Clinical Trials Research Laboratories 52

Drug Discovery World

AUGUST 1, 2023

1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. The company said: “Our preclinical research shows promising results that ASO treatment targeted to PNPLA3 reduces fat accumulation in liver cells.

RNA 130

RNA Vaccine Drugs Disease 130

The Pharma Data

OCTOBER 19, 2020

Caris’ collaborative network focused on expanding the application of precision medicine in oncology supports Winship’s enterprising approach to research leading to transformative discoveries in cancer care and treatment. IRVING, Texas and ATLANTA , Oct. Winship is one of 32 U.S. Ramalingam , M.D.,

Clinical Trials 52

Clinical Trials RNA DNA Science 52

The Pharma Data

JULY 29, 2021

The series of promising pipeline updates included the data from the landmark ZUMA-7 study for the treatment of second-line large B-cell lymphoma. Hepatitis B virus (“HBV”) and hepatitis delta virus (“HDV”) product sales increased 8% to $237 million for the second quarter 2021 compared to the same period in 2020.

Science 52

Science Production Treatment FDA 52

The Pharma Data

DECEMBER 18, 2020

. “ With the availability of two vaccines now for the prevention of COVID-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day,” said FDA Commissioner Stephen M. Hahn , M.D. It is mandatory for ModernaTX, Inc.

Vaccine 52

Vaccine FDA Clinical Trials FDA Approval 52

Codon

AUGUST 27, 2024

Consider Alice, a 49-year-old woman (and hypothetical patient) who walked into a hospital in Puerto Rico with joint pain, a headache, nausea, and a low fever. While Alice was lucky that her infections were identified at the hospital, it would have been even better had they been identified before she arrived.

DNA 84

DNA Hospitals Laboratories Virus 84

Broad Institute

JANUARY 30, 2024

In others, an infection can cause the immune system to spin out of control, leading to sepsis — organ dysfunction that lacks effective treatments and is often fatal. For his medical residency, he moved to Massachusetts General Hospital, where he was enthralled with seeing patients, especially the ones with perplexing infections.

Hospitals 137

Hospitals Medical Schools Virus Science 137

The Pharma Data

OCTOBER 21, 2020

The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., “In jointly developing and manufacturing AT-527 at scale, we seek to make this treatment option available to as many people around the world as we possibly can.”

RNA 52

RNA Pharmaceuticals Virus Small Molecule 52

The Pharma Data

DECEMBER 21, 2020

(Nasdaq:BCRX) today announced that data from part 1 of a clinical trial of its broad-spectrum antiviral, galidesivir, showed that galidesivir was safe and generally well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19. It is in advanced development for the treatment of Marburg virus disease.

Virus 52

Virus Clinical Trials RNA Trials 52

Codon

SEPTEMBER 29, 2024

But, regardless of which was first, they all operated with the same core data as their mechanism for understanding life: messenger RNA ( mRNA ). On the surface, they hadn't deviated much from the early 2020s: a virus infected a cell and released the genetic therapy hidden within. But the differences racked up the closer one looked.

Engineering 125

Engineering Virus DNA Therapies 125

Broad Institute

DECEMBER 6, 2023

Using single-cell RNA sequencing to analyze gene expression in individual cells, the researchers have found how 86 major cytokines affect 17 immune cell types in mice. For many immune-mediated diseases, there's no cure or treatment. Some patients develop resistance to treatment and we cannot predict who they will be.

Immune Response 138

Immune Response RNA Medical Schools Disease 138

The Pharma Data

JUNE 26, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza. We look forward to sharing initial results by year-end. ”. “

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

DECEMBER 27, 2020

Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study of monoclonal antibody VIR-7831 for hospitalized adults with COVID-19. Galidesivir is a broad-spectrum antiviral, an adenosine nucleoside analog that blocks viral RNA polymerase. Here’s a look. COVID-19-Related.

Clinical Trials 52

Clinical Trials Trials Therapies RNA 52

PLOS: DNA Science

MARCH 30, 2023

It is also difficult to identify with standard laboratory methods,” summed up Mahmoud Ghannoum, director of the Center for Medical Mycology at University Hospitals Cleveland Medical Center. Comparing genome sequences is important because they provide a 4-letter language in the bases A, C, G, and T (for DNA) or A, C, G, and U (for RNA).

DNA 52

DNA Hospitals Laboratories Virus 52

Codon

APRIL 9, 2023

Of those, 17 children responded to the treatment, and the 3-year overall survival rate was 60 percent. Small snippets of double-stranded RNA were sprayed onto hot pepper plants to control a pest, called Frankliniella occidentalis. The RNA strands shut down a specific gene in the insects, and killed half after 7 days.

Therapies 52

Therapies RNA Engineering Vaccine 52

The Pharma Data

JANUARY 7, 2021

.” Armstrong told the Post that the CDC hopes to more than double the number of genomic sequences of the virus posted on public websites within the next two weeks. Herd immunity will be reached when the virus encounters enough people with immunity that it dies out. ” Hospitalizations reach new records.

Virus 52

Virus Hospitals Vaccine RNA 52

PerkinElmer

OCTOBER 26, 2021

Since the World Health Organization (WHO) declared the novel coronavirus (COVID-19) outbreak a global pandemic on March 11, 2020, researchers around the world have been working tirelessly to discover effective preventive treatments and therapeutic agents. mg/mL of PPE extract or water for 4 hours.

Virus 52

Virus RNA Research Hospitals 52

PLOS: DNA Science

DECEMBER 21, 2023

I am grateful to PLoS for giving me this voice for more than a decade, and free reign to cover anything that even remotely involves DNA or RNA. FDA just approved the first CRISPR-based gene treatment , for sickle cell disease. And as the virus mutated, I was thankful for my background in genetics.

DNA 105

DNA Vaccine Science Therapies 105

The Pharma Data

OCTOBER 30, 2020

Gilead’s Veklury (remdesivir) is First Approved Treatment for COVID-19 . In October, the US Food and Drug Administration (FDA) approved the first treatment for COVID-19, Gilead’s antiviral drug Veklury (remdesivir). Veklury is a nucleotide analog RNA polymerase inhibitor and works by stopping replication of SARS-CoV-2. .

FDA Approval 52

FDA Approval Hospitals FDA Treatment 52

The Pharma Data

NOVEMBER 10, 2020

10, 2020 — Eli Lilly’s experimental antibody treatment for COVID-19 was given emergency approval by the U.S. ” The agency warned that it should not be used in patients who are already hospitalized with the illness. In early studies, researchers discovered those groups seemed to benefit the most from the treatment.

Treatment 52

Treatment Vaccine Hospitals RNA 52

The Pharma Data

DECEMBER 23, 2020

One person familiar with the list said it included the lipids that encase the RNA material in both the Moderna and Pfizer vaccines, the Times reported. Moderna and other companies that have worked more closely with Operation Warp Speed to develop their vaccines already receive favored treatment from suppliers, the Times reported.

Vaccine 52

Vaccine Government Virus Medical Schools 52